{"id":"NCT02936635","sponsor":"Cytokinetics","briefTitle":"A Study for Patients Who Completed VITALITY-ALS (CY 4031)","officialTitle":"A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-17","primaryCompletion":"2018-10-26","completion":"2018-10-26","firstPosted":"2016-10-18","resultsPosted":"2021-05-12","lastUpdate":"2021-06-15"},"enrollment":280,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"interventions":[{"type":"DRUG","name":"tirasemtiv","otherNames":["CK-2017357"]}],"arms":[{"label":"Delayed Start Treatment","type":"EXPERIMENTAL"},{"label":"Early Start Treatment","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv in ALS (CY 4031).","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"From the first dose of tirasemtiv through 28 days after the last dose","effectByArm":[{"arm":"Delayed Start Treatment","deltaMin":112,"sd":null},{"arm":"Early Start Treatment","deltaMin":157,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":67,"countries":["United States","Belgium","Canada","France","Germany","Ireland","Italy","Netherlands","Portugal","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":115},"commonTop":["Dizziness","Fatigue","Somnolence","Constipation","Muscular weakness"]}}